About Salient Surgical Technologies
Salient Surgical Technologies is a Healthcare company based in Portsmouth (United States) founded in 1999, and was acquired by Medtronic in July 2011. Electrosurgical systems for surgical resections and procedures are developed. Salient Surgical Technologies has raised $120.5 million across 7 funding rounds from investors including Medtronic, Legacy Health and BMO Global Asset Management. Its chief executive, as recorded, is Geoffery Martha. Its focus areas include Life Sciences, Gastroenterology, Medical Devices and Therapeutic Devices. Its legal entity is Salient Surgical Technologies Inc. Its competitors include CalmiGo, Xlumena and Autem Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 1999 in Portsmouth, United States, electrosurgical systems for medical applications were developed by Salient Surgical Technologies. Initial focus was placed on monopolar devices used in liver and pancreatic resections. Subsequent products included the bipolar AQUAMANTYS System, applied in orthopaedic reconstruction, spine surgery, trauma, and oncology. Acquisition by Medtronic occurred in 2011, integrating these technologies into broader surgical solutions.
- Headquarters Portsmouth, United States
- Stage Acquired
- SectorsHealthcare
- Website salientsurgical.com
- Social LinkedIn
- Acquired by Medtronic (Jul 2011)
- Legal Name Salient Surgical Technologies Inc
Funding Insights of Salient Surgical Technologies
Salient Surgical Technologies has successfully raised a total of $120.5M across 7 strategic funding rounds. The most recent funding activity was a Series G round of $15.1 million completed in January 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.5M
- Total Rounds 7
- Last Round Series G — $15.1M
- First Round $19.65M
(Oct 2000)
- Investors Count 18
All 7 funding rounds of Salient Surgical Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2010 | $15.1M | Series G | – | – | |
| Mar 2009 | $3.35M | Series F | – | – | – |
| Oct 2008 | $17.9M | Series F | – | – | |
| Jul 2007 | $20M | Series E | – | – | |
| Oct 2003 | $30M | Series D | – | – | |
| Apr 2002 | $14.5M | Series C | – | – | |
| Oct 2000 | $19.65M | Series B | – | – |
18 investors in total: 18 institutional.
Investors in Salient Surgical Technologies
Salient Surgical Technologies has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Medtronic, Legacy Health and BMO Global Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| affinitycapital.net | ||||
| rivervest.com | ||||
Expansion stage tech-focused VC firm investing primarily in the US | questm.com | Baltimore, United States | ||
Biotechnology investments are targeted by the venture capital firm. | merlinbiomed.com | New York, United States | ||
Capital and strategic direction are provided to life science companies. | mbventures.com | Memphis, United States | ||
| vanguard-ventures.com | ||||
| rahngroup.com | ||||
| crescendoventures.com | ||||
Medical equipment for treating over 30 chronic diseases is developed. | 1949 | medtronic.com | Minneapolis, United States | |
Offers wealth management, investment banking, and strategic advisory services to clients. | 1991 | arnerichmassena.com | Portland, United States |
Investor details for Salient Surgical Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Salient Surgical Technologies
1 people are tracked at Salient Surgical Technologies (1 in leadership).
| Name | Role | Group |
|---|---|---|
Geoffery Martha | CEO | Leadership |
Complete people profiles for Salient Surgical Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Salient Surgical Technologies
4 dated milestones of Salient Surgical Technologies across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Salient Surgical Technologies is founded.
- Funding First funding round of $19.6M.
- Funding Latest funding round, Series G, of $15.1M.
- Exit Acquired by Medtronic.
Competitors of Salient Surgical Technologies
Salient Surgical Technologies has 3 listed competitors in our database, 2 of them funded. They include CalmiGo, Xlumena and Autem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| calmigo.com | 2010 | New York, United States | Stress-relief devices are developed using smart breathing regulation technology. | |||
| xlumena.com | 2008 | Mountain View, United States | $73.68M | 2 | Image-guided therapeutic endoscopy devices are developed for medical procedures. | |
| autemtherapeutics.com | 2022 | Hanover, United States | $11.5M | 10 | Bioelectric platforms for cancer treatment are developed. |
Detailed competitors of Salient Surgical Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Salient Surgical Technologies (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Salient Surgical Technologies
Complete news archive for Salient Surgical Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Salient Surgical Technologies
Salient Surgical Technologies was founded in 1999 and raised its 1st funding round 1 year after it was founded.
Salient Surgical Technologies is headquartered in Portsmouth, United States. It is registered at Portsmouth, Virginia, United States.
Geoffery Martha is the CEO of Salient Surgical Technologies, as recorded in our data.
Salient Surgical Technologies is a funded company, having raised a total of $120.5M across 7 funding rounds to date. The company's 1st funding round was a Series B of $19.65M, raised on Oct 2000.
Founded in 1999 in Portsmouth, United States, electrosurgical systems for medical applications were developed by Salient Surgical Technologies. Initial focus was placed on monopolar devices used in liver and pancreatic resections. Subsequent products included the bipolar AQUAMANTYS System, applied in orthopaedic reconstruction, spine surgery, trauma, and oncology. Acquisition by Medtronic occurred in 2011, integrating these technologies into broader surgical solutions.
Salient Surgical Technologies's top competitors include CalmiGo, Xlumena and Autem Therapeutics.
Salient Surgical Technologies has 18 investors. Key investors include Medtronic, Legacy Health, BMO Global Asset Management, Piper Jaffray, and Brait.
Salient Surgical Technologies operates through Salient Surgical Technologies Inc.
Yes. Salient Surgical Technologies was acquired by Medtronic in July 2011.